NCT01014468

Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

Comparative Study - Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Instituto de Olhos de Goiania · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.

Detailed description

We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab or 0.5 mg ranibizumab and had a follow-up of at least 3 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Ranibizumab (Intravitreal injection)	Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
DRUG	Bevacizumab (Intravitreal injection)	Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-11-01
• Completion: 2012-02-01
• First posted: 2009-11-17
• Last updated: 2011-11-22

Locations

1 site across 1 country: Brazil